Curcumin-piperine supplementation modulates inflammation, oxidative stress, and cardiometabolic risk: a systematic review of randomized controlled trials.
Level 1 - systematic review of randomized trials
Systematic review of randomized controlled trials
PubMed 42232574 · doi:10.3389/fnut.2026.1814168
What was done
A systematic review was conducted across major electronic databases through 2026 to evaluate randomized controlled trials (RCTs) assessing oral curcumin in combination with piperine. Eligible studies reported outcomes related to oxidative stress, inflammation, metabolism, cardiovascular disease, or clinical symptoms across various health conditions. Methodological risk of bias was assessed for all included studies.
What was found
Twenty RCTs were included, with sample sizes ranging from 8 to 117 participants and study durations ranging from 1 to 12 weeks. Dosages ranged from 500 to 1,500 mg/day for curcumin and 5 to 15 mg/day for piperine. Significant reductions in inflammatory markers (CRP, hs-CRP, IL-6) were reported in 15 of 20 trials, and improvements in oxidative stress markers (SOD, TAC, MDA) were observed in 12 of 15 trials. Fasting blood glucose, HbA1c, and HOMA-IR decreased in metabolic syndrome and type 2 diabetes populations, while 14 of 18 trials reported reductions in lipid markers. Decreases in cardiac biomarkers (CK-MB, AST, ALT) occurred in post-CABG and acute myocardial infarction cohorts, and symptom improvements were reported for COVID-19, PMS, dysmenorrhea, and chronic pulmonary disease. No significant adverse events were reported. Thirteen trials had low risk of bias and 6 had moderate risk. The abstract provided no pooled effect sizes or confidence intervals.
Why it matters
Co-administration with piperine overcomes curcumin's low bioavailability, providing consistent multi-system biomarker improvements across diverse inflammatory and cardiometabolic conditions in short-term randomized trials.
Limits
Individual included trials were small (maximum 117 participants, minimum 8) and brief (1 to 12 weeks). Dosages and patient populations were heterogeneous, outcomes relied heavily on surrogate laboratory markers rather than hard clinical endpoints, and findings in the abstract are presented via vote counting rather than quantitative meta-analysis.
Cited by
- contradicts Black pepper used in curcumin formulations enhances bioavailability by aggravating and disrupting enterocytes, thereby increasing inflammation.